Open Payments

Childrens Mercy Hospital

Type
Teaching hospital
Where
Kansas City, MO
Medicare CCN
263302
Received
$3,027,122 in 377 records, 2022 ($184,950 general, $2,842,172 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment28$184,950
2022Research payment349$2,842,172

By company

CompanyRecordsAmountYears
PFIZER INC.38$532,0142022
JAZZ PHARMACEUTICALS INC.4$506,1852022
VERTEX PHARMACEUTICALS INCORPORATED12$378,9882022
Novartis Pharmaceuticals Corporation6$228,5502022
Edwards Lifesciences Corporation105$202,9002022
Eli Lilly and Company10$158,1572022
Abbott Laboratories6$119,6242022
ALBIREO PHARMA, INC.32$118,3892022
bioMerieux Inc8$102,4882022
Organon Llc2$83,0872022
Janssen Research & Development, LLC3$60,3002022
Boehringer Ingelheim Pharmaceuticals, Inc.2$55,9012022
Merck Sharp & Dohme LLC4$47,6222022
Gilead Sciences, Inc.27$46,1122022
Hyperfine Operations, Inc.1$44,2772022
Amgen Inc.6$42,1252022
Siemens Medical Solutions USA, Inc.3$30,6152022
Ultragenyx Pharmaceutical Inc.6$29,2512022
Alexion Pharmaceuticals, Inc.2$24,9802022
ABBVIE INC.8$24,5042022
Rhythm Pharmaceuticals, Inc.1$23,6302022
Incyte Corporation13$20,3942022
National Marrow Donor Program8$16,2072022
HEMA Biologics, LLC1$16,0002022
GLOBAL BLOOD THERAPEUTICS, INC.9$14,0142022
New York Blood Center, Inc.1$9,8402022
Genentech, Inc.3$9,5802022
Takeda Pharmaceuticals U.S.A., Inc.1$9,5002022
Boehringer Ingelheim Pharma GmbH & Co.KG2$8,8712022
Astellas Pharma Global Development3$8,7702022
Dexcom, Inc.5$8,6992022
GE HEALTHCARE1$8,5002022
Allergan, Inc.3$7,4142022
Aimmune Therapeutics, Inc.9$7,3502022
Regeneron Pharmaceuticals, Inc.2$6,6002022
Novo Nordisk AS6$4,8572022
OpGen, Inc.1$2,0002022
United Therapeutics Corporation1$1,4502022
PENTAX of America, Inc.1$1,3642022
Luminex Corporation1$1,2002022
ZOLL Medical Corporation2$1,0002022
AMAG Pharmaceuticals, Inc.1$1,0002022
Draeger Medical Systems, Inc2$7002022
Masimo Corporation8$6382022
SANOFI US SERVICES INC.1$5002022
Linvatec Corporation1$4902022
Carl Zeiss Meditec, Inc.1$1512022
Chiesi USA, Inc.1$1002022
Becton, Dickinson and Company1$1002022
Mallinckrodt Hospital Products Inc.1$1002022

By nature of payment

NatureRecordsAmount
Research payment349$2,842,172
Charitable Contribution4$100,625
Compensation for services other than consulting, including serving as faculty or as a speaker at a v7$79,780
Long term medical supply or device loan10$2,493
Space rental or facility fees (teaching hospital only)6$1,900
Debt forgiveness1$151

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Siemens Medical Solutions USA, Inc.$13,245Research paymentIn-kind items and servicesTCMH2022MRIPR9329419919961093Artz2022
2022-12-31Siemens Medical Solutions USA, Inc.$13,245Research paymentIn-kind items and servicesTCMH2022MRIPR9329419919961093Artz2022
2022-12-31Siemens Medical Solutions USA, Inc.$4,125Research paymentIn-kind items and servicesCMH2021MRIPR992Artz2022
2022-12-31Merck Sharp & Dohme LLC$166Research paymentIn-kind items and servicesRAGWITEK Biological, RESPIRATORYA Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambros2022
2022-12-31Masimo Corporation$80Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-31Masimo Corporation$80Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-31Masimo Corporation$80Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-31Masimo Corporation$80Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-31Merck Sharp & Dohme LLC$56Research paymentIn-kind items and servicesJANUVIA Drug, ENDOCRINOLOGYA Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac2022
2022-12-31Merck Sharp & Dohme LLC$19Research paymentIn-kind items and servicesSIVEXTRO Drug, INFECTIOUS DISEASEA Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Sub2022
2022-12-30bioMerieux Inc$18,000Research paymentCash or cash equivalentSpotFire R/ST Prospective Study2022
2022-12-30bioMerieux Inc$11,030Research paymentCash or cash equivalentSpotFire R/ST Prospective Study2022
2022-12-27PENTAX of America, Inc.$1,364Long term medical supply or device loanCash or cash equivalentPENTAX Device, Gastroenterology2022
2022-12-27Masimo Corporation$79Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-27Masimo Corporation$79Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-27Masimo Corporation$79Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-27Masimo Corporation$79Long term medical supply or device loanIn-kind items and servicesrainbow SET Device, Devices2022
2022-12-22Abbott Laboratories$100,000Charitable ContributionCash or cash equivalent2022
2022-12-22Gilead Sciences, Inc.$8,927Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-12-22VERTEX PHARMACEUTICALS INCORPORATED$3,114Research paymentCash or cash equivalentA Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With 2022
2022-12-22ABBVIE INC.$2,183Research paymentCash or cash equivalentLUPRON DEPOT Drug, ENDOCRINOLOGYA Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulat2022
2022-12-22ALBIREO PHARMA, INC.$1,470Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-12-22ALBIREO PHARMA, INC.$670Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-12-22Draeger Medical Systems, Inc$600Space rental or facility fees (teaching hospital only)Cash or cash equivalentBIRTHING ROOM WARMER Device, Neonatal Care & Warming Therapy2022
2022-12-22ALBIREO PHARMA, INC.$450Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-12-22ALBIREO PHARMA, INC.$397Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-12-21bioMerieux Inc$5,537Research paymentCash or cash equivalentSpotFire R/ST Prospective Study2022
2022-12-21Ultragenyx Pharmaceutical Inc.$3,632Research paymentCash or cash equivalentUX143-CL3012022
2022-12-19Edwards Lifesciences Corporation$3,580Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-12-19ABBVIE INC.$1,500Research paymentCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVEDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b2022
2022-12-19Edwards Lifesciences Corporation$300Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-12-19Edwards Lifesciences Corporation$204Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-12-16Rhythm Pharmaceuticals, Inc.$23,630Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0342022
2022-12-15PFIZER INC.$7,250Research paymentCash or cash equivalentXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANTEFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS2022
2022-12-15Eli Lilly and Company$56Research paymentIn-kind items and servicesA RANDOMIZED, OPEN-LABEL PHASE 1/2 STUDY EVALUATING RAMUCIRUMAB IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH RELAPSED, RE2022
2022-12-12Edwards Lifesciences Corporation$3,570Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-12-12Edwards Lifesciences Corporation$2,040Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-12-12Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-12-12Edwards Lifesciences Corporation$596Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-12-12Gilead Sciences, Inc.$500Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-12-12Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-12-12Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-12-12Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-12-12Gilead Sciences, Inc.$30Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2022
2022-12-07PFIZER INC.$44,171Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-07Edwards Lifesciences Corporation$2,040Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-12-07Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-12-07GLOBAL BLOOD THERAPEUTICS, INC.$90Research paymentCash or cash equivalentOXBRYTA Drug, Sickle Cell DiseaseGBT_GBT440-038_3702_012022
2022-12-05Gilead Sciences, Inc.$500Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-12-05Gilead Sciences, Inc.$60Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2022
2022-12-02Aimmune Therapeutics, Inc.$66Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2022
2022-12-02Aimmune Therapeutics, Inc.$33Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2022
2022-11-28Gilead Sciences, Inc.$4,360Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-11-25Edwards Lifesciences Corporation$15,514Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$5,600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-11-25Edwards Lifesciences Corporation$5,460Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$5,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$4,080Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-11-25Edwards Lifesciences Corporation$3,994Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$3,640Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$3,500Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$2,174Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$1,365Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$900Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-11-25Edwards Lifesciences Corporation$817Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$800Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$715Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$688Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-25Edwards Lifesciences Corporation$400Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-11-25Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-11-25Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-11-25Edwards Lifesciences Corporation$88Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112022
2022-11-23Novo Nordisk AS$630Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632022
2022-11-22bioMerieux Inc$107Research paymentCash or cash equivalentSpotFire R/ST Prospective Study2022
2022-11-16PFIZER INC.$518Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-11-15PFIZER INC.$36,421Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-11-04Catalent Pharma Solutions, LLC$25Charitable ContributionCash or cash equivalent2022
2022-11-03ALBIREO PHARMA, INC.$210Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2022
2022-11-02ABBVIE INC.$250Research paymentCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVEDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b2022
2022-10-31bioMerieux Inc$13,614Research paymentCash or cash equivalentSpotFire R/ST Prospective Study2022
2022-10-26Aimmune Therapeutics, Inc.$1,990Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2022
2022-10-21National Marrow Donor Program$2,245Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-10-20ALBIREO PHARMA, INC.$8,499Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-10-20PFIZER INC.$1,200Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2022
2022-10-20ALBIREO PHARMA, INC.$400Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-10-19Gilead Sciences, Inc.$1,300Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-10-19Gilead Sciences, Inc.$587Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2022
2022-10-13ALBIREO PHARMA, INC.$1,500Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-10-13ALBIREO PHARMA, INC.$990Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-10-13bioMerieux Inc$198Research paymentCash or cash equivalentSpotFire R/ST Prospective Study2022
2022-10-12Gilead Sciences, Inc.$220Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-10-10Edwards Lifesciences Corporation$7,650Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-10-10Edwards Lifesciences Corporation$3,600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-10-10Edwards Lifesciences Corporation$2,040Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-10-10OpGen, Inc.$2,000Research paymentCash or cash equivalentAcuitas2022
2022-10-10Edwards Lifesciences Corporation$1,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-10-10Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-10-10Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-10-10Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-10-10Gilead Sciences, Inc.$175Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2022
2022-10-07GLOBAL BLOOD THERAPEUTICS, INC.$3,000Research paymentCash or cash equivalentOXBRYTA Drug, Sickle Cell DiseaseGBT_GBT_PEDIATRIC_440-007_2926_012022
2022-10-06ALBIREO PHARMA, INC.$3,571Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-10-06ALBIREO PHARMA, INC.$2,906Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2022
2022-10-01PFIZER INC.$34,821Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-10-01bioMerieux Inc$13,500Research paymentCash or cash equivalentGI Sample Type Addition Prospective Study2022
2022-09-28PFIZER INC.$165Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-09-22ALBIREO PHARMA, INC.$16,800Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-09-22ALBIREO PHARMA, INC.$1,454Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-09-22Luminex Corporation$1,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-09-22ALBIREO PHARMA, INC.$1,013Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-09-21Gilead Sciences, Inc.$5,129Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-09-21Gilead Sciences, Inc.$1,220Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2022
2022-09-19Gilead Sciences, Inc.$555Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2022
2022-09-16GE HEALTHCARE$8,500Research paymentIn-kind items and servicesBridging the dosing gap with UGAP in pedriatic obesity2022
2022-09-15Edwards Lifesciences Corporation$5,100Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-09-15Edwards Lifesciences Corporation$3,060Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-09-15Edwards Lifesciences Corporation$2,400Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-09-15ALBIREO PHARMA, INC.$1,785Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-09-15Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-09-15Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-09-15Edwards Lifesciences Corporation$400Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-09-15Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-09-06Abbott Laboratories$3,000Research paymentCash or cash equivalentFREESTYLE LIBRE 2 Device, Diabetes CareFreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG2022
2022-09-06Abbott Laboratories$3,000Research paymentCash or cash equivalentFREESTYLE LIBRE 2 Device, Diabetes CareFreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG2022
2022-09-06ZOLL Medical Corporation$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent Device, DEFIBRILLATOR2022
2022-08-31Janssen Research & Development, LLC$3,600Research paymentCash or cash equivalentSTELARA Biological, ImmunologyCNTO1275CRD30102022
2022-08-31Janssen Research & Development, LLC$500Research paymentCash or cash equivalentSTELARA Biological, ImmunologyCNTO1275CRD30102022
2022-08-30Organon Llc$55,391Research paymentCash or cash equivalentA quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con2022
2022-08-30Organon Llc$27,695Research paymentCash or cash equivalentA quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con2022
2022-08-24PFIZER INC.$34,638Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-24Novo Nordisk AS$1,464Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632022
2022-08-24PFIZER INC.$345Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-08-24PFIZER INC.$206Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-08-23GLOBAL BLOOD THERAPEUTICS, INC.$180Research paymentCash or cash equivalentOXBRYTA Drug, Sickle Cell DiseaseGBT_GBT440-038_3702_012022
2022-08-19Novo Nordisk AS$410Research paymentIn-kind items and servicesSogroya Biological, Growth HormoneNN8640-44672022
2022-08-18ALBIREO PHARMA, INC.$1,785Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-08-17PFIZER INC.$3,789Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-11Ultragenyx Pharmaceutical Inc.$12,518Research paymentCash or cash equivalentUX143-CL3012022
2022-08-11Ultragenyx Pharmaceutical Inc.$5,120Research paymentCash or cash equivalentUX143-CL3012022
2022-08-11Ultragenyx Pharmaceutical Inc.$4,655Research paymentCash or cash equivalentUX143-CL3012022
2022-08-11Ultragenyx Pharmaceutical Inc.$1,995Research paymentCash or cash equivalentUX143-CL3012022
2022-08-11Ultragenyx Pharmaceutical Inc.$1,330Research paymentCash or cash equivalentUX143-CL3012022
2022-08-10PFIZER INC.$22,636Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-10Edwards Lifesciences Corporation$6,400Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-08-10Edwards Lifesciences Corporation$4,080Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-08-10Edwards Lifesciences Corporation$3,060Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-08-10Edwards Lifesciences Corporation$400Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-08-10Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-08-10Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-08-10Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-08-08ZOLL Medical Corporation$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent Device, DEFIBRILLATOR2022
2022-08-05National Marrow Donor Program$2,305Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-08-04PFIZER INC.$20,654Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-04ALBIREO PHARMA, INC.$11,596Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-08-04ALBIREO PHARMA, INC.$8,845Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2022
2022-08-04ALBIREO PHARMA, INC.$5,877Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-08-04ALBIREO PHARMA, INC.$2,693Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2022
2022-08-03PFIZER INC.$281Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-08-03PFIZER INC.$206Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-08-03PFIZER INC.$172Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-08-03PFIZER INC.$29Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-08-02PFIZER INC.$167,745Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-01ABBVIE INC.$5,715Research paymentCash or cash equivalentLUPRON DEPOT Drug, ENDOCRINOLOGYA Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulat2022
2022-07-28Edwards Lifesciences Corporation$8,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-07-28Edwards Lifesciences Corporation$6,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-07-28Edwards Lifesciences Corporation$4,550Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-07-28Edwards Lifesciences Corporation$4,080Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-07-28Edwards Lifesciences Corporation$3,750Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-07-28Edwards Lifesciences Corporation$3,570Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-07-28Edwards Lifesciences Corporation$600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-07-28Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012022
2022-07-28Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2022
2022-07-28Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2022
2022-07-27Gilead Sciences, Inc.$2,500Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-07-27ALBIREO PHARMA, INC.$2,340Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient2022
2022-07-27Novartis Pharmaceuticals Corporation$1,114Research paymentCash or cash equivalentKYMRIAH Biological, ONCOLOGYA SINGLE ARM PHASE II TRIAL IN FIRST LINE HIGH RISK HR PEDIATRIC AND YOUNG ADULT PATIENTS WITH BCELL ACUTE LYMPHOBLASTIC2022
2022-07-25Carl Zeiss Meditec, Inc.$151Debt forgivenessIn-kind items and services2022
2022-07-22Aimmune Therapeutics, Inc.$2,080Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2022
2022-07-22National Marrow Donor Program$257Research paymentCash or cash equivalentClinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation2022
2022-07-21GLOBAL BLOOD THERAPEUTICS, INC.$3,678Research paymentCash or cash equivalentOXBRYTA Drug, Sickle Cell DiseaseGBT_GBT440-038_3702_012022
2022-07-20Gilead Sciences, Inc.$1,460Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-07-18Abbott Laboratories$8,026Research paymentCash or cash equivalentFREESTYLE LIBRE 2 Device, Diabetes CareFreeStyle Libre 2 flash Glucose Monitoring System Intervention Phase Study for Pediatric Patients-FreeStyle Libre 22022
2022-07-18Dexcom, Inc.$85Research paymentIn-kind items and servicesDexcom G6 Transmitter Medical Supply, EndocrinologyArtificial Intelligence-enables Meal Detection to promote insulin Dose Engagement in Adolescents with Type 1 Diabetes (A2022
2022-07-15ABBVIE INC.$1,200Research paymentCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVEDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b2022
2022-07-13HEMA Biologics, LLC$16,000Research paymentCash or cash equivalentSevenFact Biological, HematologyATHN 162022
2022-07-02Novo Nordisk AS$790Research paymentIn-kind items and servicesSogroya Biological, Growth HormoneNN8640-44672022
2022-07-01bioMerieux Inc$40,500Research paymentCash or cash equivalentGI Sample Type Addition Prospective Study2022
2022-06-30JAZZ PHARMACEUTICALS INC.$135,375Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-06-29PFIZER INC.$281Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-06-29PFIZER INC.$172Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-06-29PFIZER INC.$41Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-06-29PFIZER INC.$29Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-06-27Aimmune Therapeutics, Inc.$2,080Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2022
2022-06-24Hyperfine Operations, Inc.$44,277Research paymentCash or cash equivalentSwoop Device, Portable MRIClinical Validation of Point of Care Hyperfine MRI in Children: A Pilot Study2022
2022-06-24Novartis Pharmaceuticals Corporation$105Research paymentCash or cash equivalentKYMRIAH Biological, ONCOLOGYLONG TERM FOLLOW UP OF PATIENTS EXPOSED TO LENTIVIRAL BASED CD19 DIRECTED CAR T CELL THERAPY2022
2022-06-22Gilead Sciences, Inc.$4,974Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-06-16ABBVIE INC.$3,250Research paymentCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVEDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b2022
2022-06-14Dexcom, Inc.$2,871Research paymentCash or cash equivalentDexcom G6 Transmitter Medical Supply, EndocrinologyPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2022
2022-06-14PFIZER INC.$89Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2022
2022-06-13Boehringer Ingelheim Pharmaceuticals, Inc.$55,828Research paymentCash or cash equivalentTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2022

The latest 200 records of 377.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Jackson CountyKansas City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.

MeasurePlace (city or town)
Kansas City, MO
County
Jackson County, MO
State
Missouri
Population B01003510,612719,9766,191,814
Population, 2020 census P1508,090717,2046,154,913
Median age B0100235.837.039.0
Under 18 B0100122.5%23.3%22.3%
65 and over B0100114.3%15.9%17.9%
Households B11001221,979306,7982,508,227
Foreign born B050028.6%6.6%4.5%
Median household income B19013$69,166$68,577$70,702
Median family income B19113$92,934$90,585$91,360
Per capita income B19301$41,393$39,559$39,695
Poverty rate B1700114.6%14.1%12.6%
Unemployment rate B230254.4%4.7%4.0%
Civilian labor force B23025279,828381,4333,120,639
Mean commute (minutes) B0801321.723.423.5
Bachelor's degree or higher B1500338.4%34.0%32.4%
Housing units B25001245,346336,2882,825,287
Owner-occupied B2500355.4%59.1%68.1%
Renters B2500344.6%40.9%31.9%
Median home value B25077$242,900$230,500$230,300
Median gross rent B25064$1,238$1,197$1,033
White, not Hispanic B0300254.0%59.3%76.3%
Black B0300225.2%22.0%10.9%
Hispanic or Latino B0300212.5%11.4%5.2%
Asian B030022.8%1.8%2.1%
American Indian and Alaska Native B030020.1%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.